| Title |
Long-term use of dasatinib in patients with metastatic castration-resistant prostate cancer after receiving the combination of dasatinib and docetaxel
|
|---|---|
| Published in |
Cancer Management and Research, March 2013
|
| DOI | 10.2147/cmar.s41667 |
| Pubmed ID | |
| Authors |
John C Araujo, Geralyn C Trudel, Prashni Paliwal |
| Abstract |
Dasatinib is a potent oral tyrosine kinase inhibitor which targets several kinases, including the SRC family kinases. SRC family kinases have been implicated in androgen therapy resistance that often develops in metastatic castration-resistant prostate cancer (mCRPC), which drives the need for non-androgen targeting therapies. This article describes the preclinical rationale for the use of combination dasatinib and docetaxel therapy in mCRPC, and highlights the results of a phase I-II trial in which 46 patients with mCRPC, treated with a regimen of dasatinib and docetaxel, demonstrated improvements in bone scans, high rates of soft tissue responses, and modulation of markers of bone turnover. This brief report discusses in detail follow-up data on two patients who remain alive after >2.5 years on dasatinib single-agent therapy after discontinuing docetaxel treatment. |
Mendeley readers
The data shown below were compiled from readership statistics for 13 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 8% |
| Unknown | 12 | 92% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 5 | 38% |
| Professor | 3 | 23% |
| Student > Ph. D. Student | 2 | 15% |
| Student > Bachelor | 1 | 8% |
| Student > Doctoral Student | 1 | 8% |
| Other | 0 | 0% |
| Unknown | 1 | 8% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 6 | 46% |
| Biochemistry, Genetics and Molecular Biology | 2 | 15% |
| Agricultural and Biological Sciences | 2 | 15% |
| Immunology and Microbiology | 1 | 8% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 8% |
| Other | 0 | 0% |
| Unknown | 1 | 8% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 March 2013.
All research outputs
#22,759,802
of 25,374,647 outputs
Outputs from Cancer Management and Research
#1,470
of 2,075 outputs
Outputs of similar age
#182,234
of 206,326 outputs
Outputs of similar age from Cancer Management and Research
#3
of 3 outputs
Altmetric has tracked 25,374,647 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,075 research outputs from this source. They receive a mean Attention Score of 3.5. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 206,326 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 3 others from the same source and published within six weeks on either side of this one.